Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Franco

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Breast Cancer Research and Treatment|December 3, 2005
Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)TcJuan P Oliva, Zodilina Valdés, Angel Casacó, et al.
Cancer|October 28, 2024
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011Peter H O'Donnell, Yohann Loriot, Tibor Csoszi, et al.
European Urology|October 1, 2023
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind TrialNobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, et al.
Cell|January 28, 2006
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6Raul Mostoslavsky, Katrin F Chua, David B Lombard, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Breast Cancer Research and Treatment|December 3, 2005
Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)TcJuan P Oliva, Zodilina Valdés, Angel Casacó, et al.
Cancer|October 28, 2024
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011Peter H O'Donnell, Yohann Loriot, Tibor Csoszi, et al.
European Urology|October 1, 2023
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind TrialNobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, et al.
Cell|January 28, 2006
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6Raul Mostoslavsky, Katrin F Chua, David B Lombard, et al.
Pageof 6